To establish a company that would in turn help create a healthier China, Simcere was founded in 1995. The company has swiftly evolved from being a pure distributor of pharmaceutical products to become a leading manufacturer and supplier of drugs in the rapidly growing China pharmaceutical market. It now have six certified Good Manufacturing Practices ("GMP") manufacturing facilities, two nationwide sales and marketing subsidiaries, a research and development center and over 3,000 employees. In recent years, Simcere has continued to refine its strategy to focus on the development of first-to-market generic and innovative pharmaceuticals. It currently manufactures and sells 39 principal pharmaceutical products and is the exclusive distributor of three additional pharmaceuticals that are manufactured by independent third parties but marketed under its brand. In addition, its innovative anti-cancer medication Endu was granted an invention patent in China and was the first recombinant human endostatin injection approved for sale in China. And its generic anti-stroke medication Bicun was the first edaravone injection, a type of neuroprotective pharmaceutical compound, approved for sale in China. Going forward, Simcere wishes to become a leading Chinese pharmaceutical company by providing innovative medicines that will reshape the future of the pharmaceutical industry in China.